{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:15:13Z","timestamp":1761488113921},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Supportive Cancer Therapy"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.3816\/sct.2007.n.004","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:12:31Z","timestamp":1221081151000},"page":"101-109","source":"Crossref","is-referenced-by-count":2,"title":["Balancing Risk and Benefit for First-Line Treatment of Metastatic Colorectal Cancer: A Graphic Communication Tool for Patients and Physicians"],"prefix":"10.3816","volume":"4","author":[{"given":"Michael S.","family":"Sanatani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/SCT.2007.n.004_bib1","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","article-title":"Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors","volume":"16","author":"Meta-Analysis Group in Cancer","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib2","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","article-title":"Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study","volume":"15","author":"DeGramont","year":"1997","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/SCT.2007.n.004_bib4","first-page":"149s","volume":"24","author":"Falcone","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/annonc\/mdi047","article-title":"A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity","volume":"16","author":"Borner","year":"2005","journal-title":"Ann Oncol"},{"issue":"16 suppl","key":"10.3816\/SCT.2007.n.004_bib6","first-page":"265s","article-title":"Dose reduced first-line capecitabine monotherapy in older and less fit patients with advanced colorectal cancer","volume":"23","author":"Vincent","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1179\/joc.2004.16.5.487","article-title":"Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: is this really a dangerous treatment?","volume":"16","author":"Idelevich","year":"2004","journal-title":"J Chemotherapy"},{"key":"10.3816\/SCT.2007.n.004_bib8","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdf183","article-title":"Multicentre non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients","volume":"13","author":"Seitz","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdh158","article-title":"Phase I\/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer","volume":"15","author":"Aranda","year":"2004","journal-title":"Ann Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib10","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/sj.bjc.6601713","article-title":"Irinotecan plus raltitrexed as firstline treatment in advanced colorectal cancer: a phase II study","volume":"90","author":"Feliu","year":"2004","journal-title":"Brit J Cancer"},{"key":"10.3816\/SCT.2007.n.004_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1200\/JCO.2004.05.188","article-title":"Multicentre phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer","volume":"22","author":"Sorbye","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib12","doi-asserted-by":"crossref","first-page":"247s","DOI":"10.1200\/jco.2005.23.16_suppl.3507","article-title":"Infusional 5-fluorouracil\/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): results of the safety and efficacy analysis","volume":"23","author":"Arkenau","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib13","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1200\/JCO.2003.02.071","article-title":"Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer","volume":"21","author":"Hochster","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.20.1.165","article-title":"Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer","volume":"20","author":"Scheithauer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib15","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO.2004.11.069","article-title":"XELOX (capecitabine plus oxaliplatin): active first line therapy for patients with metastatic colorectal cancer","volume":"22","author":"Cassidy","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib16","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1200\/JCO.2005.05.546","article-title":"Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986","volume":"23","author":"K\u00f6hne","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib17","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1200\/JCO.2003.11.122","volume":"21","author":"K\u00f6hne","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR Study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib19","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"DeGramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib20","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/sj.bjc.6603011","volume":"94","author":"Souglakos","year":"2006","journal-title":"Br J Cancer"},{"key":"10.3816\/SCT.2007.n.004_bib21","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1200\/JCO.2005.05.546","article-title":"Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986","volume":"23","author":"K\u00f6hne","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib22","first-page":"129a","article-title":"Phase III study of bolus 5-fluorouracil (5-FU)\/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion\/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer","volume":"21","author":"Grothey","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"22","author":"Goldberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer","volume":"343","author":"Saltz","year":"2001","journal-title":"N Eng J Med"},{"key":"10.3816\/SCT.2007.n.004_bib25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","article-title":"OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study","volume":"24","author":"Tournigand","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib26","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/annonc\/mdi185","volume":"16","author":"Comella","year":"2005","journal-title":"Ann Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib27","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0140-6736(02)08514-8","article-title":"Comparison of survival, palliation, and QOL with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial","volume":"359","author":"Maughan","year":"2002","journal-title":"Lancet"},{"key":"10.3816\/SCT.2007.n.004_bib28","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.1989.7.10.1419","article-title":"The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial","volume":"7","author":"Petrelli","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1023\/A:1008282824860","article-title":"Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study","volume":"9","author":"Aranda","year":"1998","journal-title":"Ann Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib30","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2006.06.1317","article-title":"Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial","volume":"24","author":"Goldberg","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/SCT.2007.n.004_bib31","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/bmj.321.7260.531","article-title":"Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis","volume":"321","author":"Colorectal Cancer Collaborative Group","year":"2000","journal-title":"Brit Med J"}],"container-title":["Supportive Cancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543291213600260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543291213600260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T19:05:49Z","timestamp":1557774349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1543291213600260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S1543291213600260"],"URL":"https:\/\/doi.org\/10.3816\/sct.2007.n.004","relation":{},"ISSN":["1543-2912"],"issn-type":[{"value":"1543-2912","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}